01066.HK
Shandong Weigao Group Medical Polymer Company Limited
HKSE · Healthcare · Medical - Instruments & Supplies · CN
HKD 3.27
+1.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 26.6B | 13.4B | 13.1B | 13.2B | 13.6B |
| Cost of Revenue | 14.0B | 7.1B | 6.5B | 6.6B | 6.5B |
| Gross Profit | 12.6B | 6.3B | 6.6B | 6.6B | 7.3B |
| Operating Expenses | |||||
| R&D Expense | 1.4B | 794.0M | 625.2M | 731.4M | 546.6M |
| SG&A Expense | 7.4B | 3.8B | 3.6B | 3.8B | 3.5B |
| General & Admin Expense | 2.1B | 1.4B | 1.3B | 1.2B | 1.1B |
| Selling & Marketing Expense | 3.5B | 2.4B | 2.3B | 2.6B | 2.5B |
| Other Expenses | — | — | (59.6M) | (217.7M) | (124.7M) |
| Total Operating Expenses | 8.8B | 4.6B | 4.2B | 4.3B | 4.0B |
| Cost and Expenses | 22.8B | 11.7B | 10.7B | 11.2B | 10.5B |
| Operating Income (EBIT) | 3.8B | 1.7B | 2.4B | 2.0B | 2.9B |
| Non-Operating | |||||
| Interest Income | 111.8M | 183.6M | 230.4M | 235.7M | 181.4M |
| Interest Expense | 369.0M | 249.2M | 249.6M | 273.0M | 191.4M |
| Net Interest Income | (257.2M) | (65.7M) | (19.1M) | (37.3M) | (10.0M) |
| Other Non-Op Income/Expense | 414.6M | 332.6M | 167.6M | 326.6M | 461.3M |
| Non-Operating Income (excl Interest) | (147.4M) | (147.4M) | 113.3M | (345.1M) | (118.2M) |
| EBT (Pre-Tax Income) | 4.2B | 2.0B | 2.6B | 2.4B | 3.4B |
| Income Tax Expense | 708.7M | 320.8M | 391.0M | 307.6M | 435.6M |
| Bottom Line | |||||
| Net Income | 3.3B | 1.6B | 2.1B | 2.0B | 2.8B |
| Earnings from Cont. Ops | 3.5B | 1.7B | 2.2B | 2.1B | 3.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.3B | 1.6B | 2.1B | 2.0B | 2.8B |
| Per Share | |||||
| Basic EPS | HK$0.72 | HK$0.35 | HK$0.46 | HK$0.44 | HK$0.61 |
| Diluted EPS | HK$0.72 | HK$0.35 | HK$0.45 | HK$0.44 | HK$0.61 |
| Revenue Per Share | HK$5.88 | HK$2.95 | HK$2.88 | HK$2.93 | HK$3.02 |
| Shares | |||||
| Basic Shares Outstanding | 4.5B | 4.5B | 4.5B | 4.5B | 4.5B |
| Diluted Shares Outstanding | 4.5B | 4.5B | 4.5B | 4.5B | 4.5B |
| Profitability Metrics | |||||
| EBITDA | 5.8B | 2.8B | 3.1B | 3.6B | 4.4B |
| D&A | 1.8B | 906.3M | 869.4M | 911.7M | 803.1M |
| EBIT | 4.0B | 1.8B | 2.3B | 2.6B | 3.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026